Evidence map›Paper›PMID 42675918›Full record

Trial reportRenal failure2026

Efficacy and safety of ferric citrate tablets in Chinese patients with hyperphosphatemia undergoing maintenance hemodialysis: a multicenter, randomized, open-label, active-controlled, phase III trial.

Jie Ma, Bicheng Liu, Jialiang Pang, Pei Wang, Ying Li, Caili Wang, Donghui Zheng, Xiaoping Wang, Xiumei Hu, Jianrong Zhao and 18 more

Abstract readMulticenter StudyRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Jie MaDepartment of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Bicheng LiuDepartment of Nephrology, Zhongda Hospital, Southeast University, Nanjing, China.
Jialiang PangBlood Purification Center, Xinxiang First People's Hospital, Xinxiang, China.
Pei WangBlood Purification Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ying LiDepartment of Nephrology, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
Caili WangDepartment of Nephrology, The Frist Affiliated Hospital Baotou Medical College, Baotou, China.
Donghui ZhengDepartment of Nephrology, Huai'an Second People's Hospital, Huai'an, China.
Xiaoping WangDepartment of Nephrology, Blood Purification Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Xiumei HuDepartment of Nephrology, Zhuzhou Central Hospital/Zhuzhou Hospital, Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, China.
Jianrong ZhaoDepartment of Nephrology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Xinzhou ZhangDepartment of Nephrology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, Shenzhen, China.
Changchun CaoDepartment of Nephrology, Sir Run Run Hospital Nanjing Medical University, Nanjing, China.
Zunsong WangDepartment of Nephrology, The First Affiliated Hospital of Shandong First Medical University, Shandong Provincial Qianfoshan Hospital, Jinan, China.
Li XingHemodialysis Room, People's Hospital of Zhengzhou, Zhengzhou, China.
Suhua LiNephrology Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Hong ChengDepartment of Nephrology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Jian HuangDepartment of Nephrology, Jinhua Municipal Central Hospital, Jinhua, China.
Yi YangDepartment of Nephrology, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China.
Xiaolan ChenDepartment of Nephrology, Affiliated Hospital of Nantong University, Nantong, China.
Kun YeDepartment of Nephrology, The People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Academy of Medical Sciences, Nanning, China.
Tiekun YanDepartment of Nephrology, Tianjin Medical University General Hospital, Tianjin, China.
Lianhua ChenDepartment of Nephrology, Huai'an First People's Hospital, Huai'an, China.
Guojuan ZhangDepartment of Nephrology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Feng ZhengDepartment of Nephrology, The Second Affiliated Hospital of Dalian, Medical University, Dalian, China.
Siyuan TengDepartment of Nephrology, The Second Affiliated Hospital of Dalian, Medical University, Dalian, China.
Qing ZhuDepartment of Nephrology, Henan Provincial People's Hospital, Zhengzhou, China.
Hong LiuDepartment of Nephrology, the Second Xiangya Hospital of Central South University, Changsha, China.ORCID 0000-0001-6040-5323
Xuemei LiDepartment of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to evaluate the efficacy and safety of ferric citrate tablets in Chinese patients with hyperphosphatemia undergoing maintenance hemodialysis (MHD).

methodsIn this phase III, multicenter, randomized, open-label, non-inferiority trial, patients with hyperphosphatemia on maintenance hemodialysis were randomly assigned to receive either ferric citrate or sevelamer carbonate tablets for 12 weeks. The primary endpoint was the change in serum phosphorus levels from baseline to week 12, with a non-inferiority margin of 0.32 mmol/L. Secondary endpoints included changes in serum calcium, intact parathyroid hormone, and safety assessments.

resultsA total of 239 patients were randomized to the ferric citrate group (

conclusionsFerric citrate tablets were non-inferior to sevelamer carbonate in reducing serum phosphorus levels in hyperphosphatemia patients on maintenance hemodialysis, with the added benefit of improving iron-related anemia and a favorable safety profile.

Indexed as

Ferric CompoundsHyperphosphatemiaKidney Failure, ChronicRenal DialysisSevelamerAdultAgedCalciumChelating AgentsChinaFemaleHumansMaleMiddle AgedParathyroid HormonePhosphorusCalciumChelating Agentsferric citrateFerric CompoundsParathyroid HormonePhosphorusSevelamerTabletsChronic kidney diseaseferric citratehemodialysishyperphosphatemiairon-based phosphorus binder

Identifiers

PMID42675918
PMCPMC13537050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.